Alison Jane Williamson

Gardant Pharmaceuticals, Inc. develops and commercializes pharmaceutical compounds. It develops network for research, clinical development, and project management and guides them through the clinical development and licensing stages. The company was founded in 2000 and is headquartered in New York, NY

Caldan Therapeutics Ltd. provides novel therapeutics targeting free fatty acid. It focuses on developing drugs in order to deliver anti-diabetic effects in multiple tissues and organs. The company was founded by Graeme Milligan and Trond Ulven and is headquartered in Edinburgh, the United Kingdom.

Xceleron, Inc. provides drug development and biomedical research services. Its services include pharmaceutical and analytical method quality. The company was founded by Colin Garner in 1997 and is headquartered in Germantown, MD.

Phoqus Pharmaceuticals Plc develops pharmaceutical products. It's product Chronocort that helps to treat the patients with cortisol deficiency such as congenital adrenal hyperplasia and Addison's diseases. The company was founded in 1998 and is located in West Malling, UK.

Newcells Biotech Ltd. operates as a biotechnology company which produces induced pluripotent stem cells and reproducible cell and tissues. Its cell products include human neural progenitor and cardiomyocyte. The firm also provides reprogramming and differentiation services and products. The company was founded by Majlinda Lako and Lyle Armstrong in 2014 and is headquartered in Newcastle Upon Tyne, the United Kingdom.

Enhanc3D Genomics is a private functional genomics company based in Cambridge, UK. Enhanc3D Genomics is developing a technology to unlock the full potential of the three-dimensional organization of the human genome. The British company's focus is on the non-coding regions of the genome, aiming to identify disease-associated genetic interactions and revolutionize target and biomarker discovery. The company's unique approach has the potential to make precision medicine an everyday reality for patients. Enhanc3D Genomics Ltd. was founded by Mikhail Spivakov, Peter Fraser, and Stefan Schönfelder. The CEO is Hazel Jones.

Epidarex Capital Partners LLC (Epidarex Capital) is a venture capital firm founded in 2010 by Kyparissia Sirinakisvin. The firm is headquartered in Bethesda, Maryland.

Bloomsbury Genetic Therapies Ltd. is a British biotechnology company that specializes in developing gene therapy technologies for neurological and metabolic diseases. The company is based in Cambridge, UK. Bloomsbury Genetic Therapies was founded in 2021 by Adrien Lemoine, who has been the CEO since 2021.

TranScrip Partners LLP is a consultancy provider for biotech and pharmaceutical companies. TranScrip Partners was founded in 2008 and is based in Wokingham, UK. The British company offers development and commercialization services to its clients.

CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT.

Healthcare Royalty Management LLC (Healthcare Royalty) is a private equity subsidiary of Cowen, Inc. founded in 2007 by Gregory Brown. The firm is headquartered in Stamford, Connecticut.

454 Life Sciences Corp. engages in the provision of medical testing services to determine the nucleotide sequence of whole genomes. The company was founded by Jonathan M. Rothberg in 2000 and is headquartered in Branford, CT.

Part of Boston Scientific Corp., Provensis Ltd. is a British company that provides health care services. The company is based in Camberley, UK. The company was founded in 1999 by Paul Bernard Harper.

Cardiorentis AG operates as a biopharmaceutical company. It offers novel therapies to the treatment of heart failure and related cardiovascular diseases. The company was founded in 2010 and is headquartered in Zug, Switzerland.

Summit Therapeutics Ltd. operates as a holding company, which engages in the discovery, development, and commercialization of antibiotic medicines. The company seeks to expand its product candidate portfolio through the development of new mechanism and precision antibiotics. Summit Therapeutics was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, the United Kingdom.

Merck Serono SA operates as a holding company in the pharmaceutical field. It engages in the research, development, manufacture, and distribution of therapeutic products for the treatment of human diseases. The company was founded on May 21, 1987 and is headquartered in Coinsins, Switzerland.

Zeneca Pharmaceuticals manufactures medicines.

Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland.

Part of Rethmann SE & Co. KG, Pharma Action GmbH is a German pharmaceutical company that manufactures pharmaceutical products. The company is based in Berlin, Germany. The CEOs of the company are Erol Isim, Carl E. Bürger. Pharma Action was acquired by Bioibérica SA from Tönnies Lebensmittel GmbH & Co. KG on November 16, 2017.

Entelos, Inc. develops predictive computer models of human disease. Its solutions include mechanism-based, mathematical models; virtual patients, populations; biosimulation software and biosimulation expertise. The company was founded in 1996 and is headquartered in San Mateo, CA.

Edinburgh Molecular Imaging Ltd. develops optical molecular imaging technology, which includes optical imaging, cancer imaging and lung imaging. The firm's molecular imaging technology, based on Fluorescent Imaging, has the potential to detect disease in real-time during interventional procedures including surgery, providing more accurate treatment while sparing healthy tissue. The company was founded by Chris Haslett, Kev Dhaliwal and Mark Bradley in February 2014 and is headquartered in Edinburgh, the United Kingdom.